• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2011 Fiscal Year Annual Research Report

HCV蛋白とインターフェロン系との相互作用のFRET/BRET解析

Research Project

Project/Area Number 21590831
Research InstitutionTokyo Medical and Dental University

Principal Investigator

藤田 めぐみ (田坂 めぐみ)  東京医科歯科大学, 大学院・医歯学総合研究科, 特任助教 (50510369)

Co-Investigator(Kenkyū-buntansha) 坂本 直哉  東京医科歯科大学, 大学院・医歯学総合研究科, 寄附講座教員 (10334418)
東 正新  東京医科歯科大学, 医学部附属病院, 助教 (10376783)
KeywordsHCVレプリコン / インターフェロン / RIG-I
Research Abstract

本研究において申請者は、生体における抗ウイルス免疫応答に中心的な役割を果たしているインターフェロン(IFN)系と、C型肝炎ウイルス(HCV)感染との関わりを解明するため、独自に開発したHCV増殖・培養細胞系を用いて分子イメージング技術により、病原体侵入により惹起されるIFN産生系を抑制するHCV蛋白、NS4BおよびNS34Aの分子間相互作用の解析をすすめ、以下の結果を得た。(1)NS4B、RIG-I,Cardif蛋白発現プラスミドに蛍光蛋白Kusabira-GreenのN末端側、およびC末端側の切断蛋白を癒合した発現プラスミドを構築し、細胞内強制発現にてそれらの分子間結合をBi-molecular Fluorescent Complementation(BiFC) assayにより検出したところ、NS4Bがインターフェロン誘導アダプター蛋白であるSTINGと強固に結合し、その活性を抑制することを見いだした。種々のエピトープを欠失したNS4B発現プラスミドを用いることにより、NS4BのN末端側1-72アミノ酸が相互作用に関連した領域であることを明らかとした。(2)HCV-NS4BとCardif,RIG-Iの免疫沈降:により、NS4B蛋白がSTINGとCardifの分子間結合を阻害し、インターフェロンシグナル活性化を遮断することを明らかとした。本研究の成果を元に、HCV感染細胞におけるインターフェロン不応性のメカニズムを明らかとしてNS4Bを標的とした新たな分子標的療法樹立に向けた研究を遂行する。

Current Status of Research Progress
Current Status of Research Progress

1: Research has progressed more than it was originally planned.

Reason

HCV感染細胞でインターフェロン応答シグナルを遮断するウイルス蛋白NS4BがSTINGの特定のドメインを標的とすることを世界で初めて明らかとしている。

Strategy for Future Research Activity

本研究の成果を元に、HCV感染細胞におけるNS4B、SN34Aを介したインターフェロン不応性のメカニズムを明らかとし、NS4Bを標的とした新たな分子標的療法樹立に向けた研究を遂行する。すでにNS4B阻害薬による抗ウイルス効果、インターフェロンシグナル抑制効果の解析準備を進めている。

  • Research Products

    (36 results)

All 2012 2011

All Journal Article (22 results) (of which Peer Reviewed: 22 results) Presentation (13 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication2012

    • Author(s)
      Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyonashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M
    • Journal Title

      Antimicrob Agent Chemother

      Volume: 56(3) Pages: 1315-23

    • DOI

      doi:10.1128/AAC.05764-11

    • Peer Reviewed
  • [Journal Article] Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives2012

    • Author(s)
      Kaushik-Basu N, Sakamoto N
    • Journal Title

      Eur J Med Chem

      Volume: 49 Pages: 191-199

    • DOI

      10.1016/j.ejmech.2012.01.010

    • Peer Reviewed
  • [Journal Article] Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis2012

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Journal Title

      Antivir Ther

      Volume: 17(1) Pages: 35-43

    • Peer Reviewed
  • [Journal Article] Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C2012

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Journal Title

      J Hepatol

      Volume: 56(3) Pages: 602-608

    • DOI

      10.1016/j.jhep.2011.09.011

    • Peer Reviewed
  • [Journal Article] Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 912011

    • Author(s)
      Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, Watanabe T, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K,Watanabe M
    • Journal Title

      J Virol

      Volume: 85 Pages: 5986-94

    • DOI

      doi:10.1128/JVI.02583-10

    • Peer Reviewed
  • [Journal Article] Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture2011

    • Author(s)
      Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Kato T, Wakita T, Watanabe M
    • Journal Title

      Hepatol Res

      Volume: 41 Pages: 258-269

    • DOI

      doi:10.1111/j.1872-034X.2010.00771.x

    • Peer Reviewed
  • [Journal Article] Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response2011

    • Author(s)
      Asahina Y, Sakamoto N, et al
    • Journal Title

      Hepatology

      Volume: 55(1) Pages: 20-29

    • DOI

      10.1002/hep.24623

    • Peer Reviewed
  • [Journal Article] Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy2011

    • Author(s)
      Kadokura M, Sakamoto N, et al
    • Journal Title

      Hepatol Int

      Volume: 5(3) Pages: 789-799

    • DOI

      10.1007/s12072-011-9267-x

    • Peer Reviewed
  • [Journal Article] Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection2011

    • Author(s)
      Yoshida T, Sakamoto N, et al
    • Journal Title

      Biochem Biophys Res Commun

      Volume: 416(1-2) Pages: 119-124

    • DOI

      10.1016/j.bbrc.2011.11.007

    • Peer Reviewed
  • [Journal Article] A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors2011

    • Author(s)
      Takaya D, Sakamoto N, et al
    • Journal Title

      Bioorganic & Medicinal Chemistry

      Volume: 19(22) Pages: 6892-6905

    • DOI

      10.1016/j.bmc.2011.09.023

    • Peer Reviewed
  • [Journal Article] Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin2011

    • Author(s)
      Ueyama M, Sakamoto N, et al
    • Journal Title

      Antivir Ther

      Volume: 16 Pages: 1081-1091

    • Peer Reviewed
  • [Journal Article] Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C2011

    • Author(s)
      Tanaka Y, Sakamoto N, et al
    • Journal Title

      Human Molecular Genetics

      Volume: 20(17) Pages: 3507-3516

    • DOI

      10.1093/hmg/ddr249

    • Peer Reviewed
  • [Journal Article] Pretreatment Prediction of Anemia Progression by Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C : Decision-Tree Analysis2011

    • Author(s)
      Hiramatsu N, Sakamoto N, et al
    • Journal Title

      J Gastroenterol

      Volume: 46(9) Pages: 1111-1119

    • DOI

      10.1007/s00535-011-0412-z

    • Peer Reviewed
  • [Journal Article] Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy2011

    • Author(s)
      Kadokura M, Sakamoto N, et al
    • Journal Title

      PLoS One

      Volume: 6(9) Pages: e24514

    • DOI

      10.1371/journal.pone.0024514

    • Peer Reviewed
  • [Journal Article] Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis2011

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Journal Title

      J Gastroenterol

      Volume: 46(3) Pages: 401-409

    • DOI

      10.1007/s00535-010-0322-5

    • Peer Reviewed
  • [Journal Article] Adenovirus vector-mediated assay system for hepatitis C virus replication2011

    • Author(s)
      Yoshida T, Sakamoto N, et al
    • Journal Title

      Nucleic Acids Res

      Volume: 39(10) Pages: e64

    • DOI

      10.1093/nar/gkr047

    • Peer Reviewed
  • [Journal Article] Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection2011

    • Author(s)
      Watanabe T, Sakamoto N, AzumaS, et al
    • Journal Title

      Antimicrob Agents Chemother

      Volume: 55(6) Pages: 2537-2545

    • DOI

      10.1128/AAC.01780-10

    • Peer Reviewed
  • [Journal Article] Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes2011

    • Author(s)
      Toyoda M, Sakamoto N, et al
    • Journal Title

      Int J Mol Med

      Volume: 27 Pages: 619-624

    • DOI

      10.3892/ijmm.2011.622

    • Peer Reviewed
  • [Journal Article] Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotytypes 2a and 2b2011

    • Author(s)
      Sakamoto N, Azuma S, et al
    • Journal Title

      J Med Virol

      Volume: 83 Pages: 871-878

    • DOI

      10.1002/jmv.22038

    • Peer Reviewed
  • [Journal Article] Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice2011

    • Author(s)
      Onozuka I, Sakamoto N, et al
    • Journal Title

      Biochem Biophys Res Commun

      Volume: 406 Pages: 134-140

    • DOI

      10.1016/j.bbrc.2011.02.012

    • Peer Reviewed
  • [Journal Article] Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors2011

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Journal Title

      J Hepatol

      Volume: 54 Pages: 439-448

    • DOI

      10.1016/j.jhep.2010.07.037

    • Peer Reviewed
  • [Journal Article] Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin : data mining analysis2011

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Journal Title

      J Med Virol

      Volume: 83 Pages: 445-452

    • DOI

      10.1002/jmv.22005

    • Peer Reviewed
  • [Presentation] IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones2011

    • Author(s)
      Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Watanabe M
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] ITPA gene variant protects against treatment-induced anemia and improves viral clearance by pegylated interferon-alfa and ribavirin therapy in chronic hepatitis C patients2011

    • Author(s)
      Sakamoto N, Azuma S, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] MMP-2 and MMP-14 derived from donor cells enhance therapeutic efficacy of liver cell transplantation in mice2011

    • Author(s)
      Kakinuma S, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] A high-content screening assay using infectious fluorescence-tagged hepatitis C virus reveals candidates for small molecule inhibitors of viral entry2011

    • Author(s)
      Kusano-Kitazume A, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] Loww of Wnt5A promotes biliary differentiation of murine hepatic stem/progenitor cells2011

    • Author(s)
      Kiyohashi K, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] Antiviral effect of a novel interferon-inducible protein, IFI-27, against hepatitis C virus replication2011

    • Author(s)
      Itsuil Y, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] Prediction model of ribavirin-induced anemia incorporating ITPA genotype could identify chronic hepatitis C patients at high risk of relapse among virological responders to pegylated-interferon and ribavirin2011

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] IL28B and ITPA gene variants correlate with treatment efficacy in pegylated-interferon plus ribavirin therapy for chronic hepatitis C2011

    • Author(s)
      Matsuura K, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] Mutations in the interferon sensitivity determining region of HCV, age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy2011

    • Author(s)
      Kurosaki M, Sakamoto N, et al
    • Organizer
      62th. Annual Meeting of American Association for the Study of Liver Diseases
    • Place of Presentation
      San Francisco
    • Year and Date
      2011-11-04
  • [Presentation] Development of an RNA polymerase I-driven adenoviral vector and its application in an HCV replication assay2011

    • Author(s)
      Yoshida T, Sakamoto N, et al
    • Organizer
      18th. International Meeting on Hepatitis C Virus & Related Viruses
    • Place of Presentation
      Seattle
    • Year and Date
      2011-09-08
  • [Presentation] Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 912011

    • Author(s)
      Sakamoto N, et al
    • Organizer
      18th. International Meeting on Hepatitis C Virus & Related Viruses
    • Place of Presentation
      Seattle
    • Year and Date
      2011-09-08
  • [Presentation] HCV-NS4B targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immune response2011

    • Author(s)
      Nitta S, Sakamoto N, Tasaka-Fujita M, et al
    • Organizer
      18th. International Meeting on Hepatitis C Virus & Related Viruses
    • Place of Presentation
      Seattle
    • Year and Date
      2011-09-08
  • [Presentation] Development of RNA pol-driven adenovirus vector expressing hepatitis C virus replicon2011

    • Author(s)
      Yamagishi Y, Sakamoto N, et al
    • Organizer
      Experimental Biology 2011
    • Place of Presentation
      Washington
    • Year and Date
      2011-04-13
  • [Patent(Industrial Property Rights)] C型肝炎ウイルスの増殖を抑制する医薬組成物2011

    • Inventor(s)
      坂本直哉、渡辺守、北詰晶子、萩原正敏、奥野友紀子
    • Industrial Property Rights Holder
      東京医科歯科大学
    • Industrial Property Number
      特願2011-194082
    • Filing Date
      2011-09-06

URL: 

Published: 2013-06-26   Modified: 2013-11-07  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi